SCHEMBL474941

SCHEMBL474941

O=C(Nc1ccccc1)C(F)(F)F

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.65
HDAC7 Q8WUI4 3/20 0.65
HDAC8 Q9BY41 3/20 0.65
HDAC6 Q9UBN7 3/20 0.65
HDAC3 O15379 2/20 0.65
HDAC4 P56524 2/20 0.65
HDAC2 Q92769 2/20 0.65
HDAC10 Q969S8 2/20 0.65
HDAC11 Q96DB2 2/20 0.65
HDAC9 Q9UKV0 2/20 0.65
HDAC5 Q9UQL6 2/20 0.65
PDK1 Q15118 2/20 0.63
PDK2 Q15119 2/20 0.63
PDK3 Q15120 2/20 0.63
PDK4 Q16654 2/20 0.63
L3MBTL1 Q9Y468 1/20 0.61
KMT2A Q03164 5/20 0.60
MEN1 O00255 4/20 0.60
RAB9A P51151 3/20 0.60
TP53 P04637 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5917247 0.96 HDAC1 (0.61) HDAC1HDAC7HDAC8HDAC6HDAC3
SCHEMBL5403029 0.92 CA12 (0.59) HDAC1HDAC7HDAC8HDAC6HDAC3
SCHEMBL28023108 0.90 CA12 (0.57) HDAC1HDAC7HDAC8HDAC6HDAC3
SCHEMBL8755361 0.88 RAB9A (0.71) HDAC1HDAC7HDAC8HDAC6HDAC3
SCHEMBL3765919 0.84 CA12 (0.59) HDAC1HDAC7HDAC8HDAC6HDAC3
SCHEMBL20981664 0.84 L3MBTL1 (0.82) HDAC1HDAC7HDAC8HDAC6HDAC3
SCHEMBL9677254 0.84 PDK1 (0.61) HDAC1HDAC7HDAC8HDAC6HDAC3
SCHEMBL17272756 0.83 PDK1 (0.70) HDAC1HDAC7HDAC8HDAC6HDAC3
SCHEMBL6622461 0.83 HDAC1 (0.71) HDAC1HDAC7HDAC8HDAC6HDAC3
SCHEMBL11426260 0.83 HDAC1 (0.66) HDAC1HDAC7HDAC8HDAC6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 550 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282810-A1 Chemical Synthesis Method and Application of V. Cholerae Serotype O100 O-Antigen Oligosaccharides JIANGNAN UNIVERSITY (CN) 2025-09-11 US claimed
CN-116396319-B Trifluoroacetanilide compound and preparation method and application thereof 中国烟草总公司郑州烟草研究院 2024-08-16 CN claimed
CN-118496286-A Chemical synthesis method of vibrio vulnificus organism type 2A serotype O-antigen disaccharide fragment 江南大学 2024-08-16 CN claimed
CN-118440133-A Sulfated fucosylated glucuronic acid mannooligosaccharide and preparation method thereof 中国海洋大学 2024-08-06 CN claimed
CN-118420796-A Synthesis method and application of campylobacter jejuni CG8486 capsular oligosaccharide and glycoprotein conjugate thereof 中国海洋大学 2024-08-02 CN claimed
CN-115232177-B Chemical synthesis method of shigella dysenteriae 10 type O-antigen oligosaccharide 江南大学 2024-07-30 CN claimed
US-12018306-B2 Method for chemically synthesizing Helicobacter pylori core lipopolysaccharide oligosaccharide antigen carbohydrate chain JIANGNAN UNIVERSITY (CN) 2024-06-25 US claimed
CN-118206496-A Method for preparing uracil compound containing carboxylic ester fragment under acidic condition 江苏中旗科技股份有限公司 2024-06-18 CN claimed
US-20240068001-A1 Method for Chemically Synthesizing Helicobacter pylori Core Lipopolysaccharide Oligosaccharide Antigen Carbohydrate Chain JIANGNAN UNIVERSITY (CN) 2024-02-29 US claimed
CN-117447296-A Preparation method of p-chloroiodobenzene-14C 长沙贝塔医药科技有限公司 2024-01-26 CN claimed
CN-1798729-A Benzamide nitrile derivatives HOFFMANN LA ROCHE (CH) 2006-07-05 CN claimed
CN-1795179-A Novel imidazole derivatives, the production thereof, and the use of the same as a medicament SOD CONSEILS RECH APPLIC (FR) 2006-06-28 CN claimed
CN-1221529-C Substituted N- [ (aminoiminomethyl or aminomethyl) phenyl ] propyl amides ARVENTIS PHARMACEUTICALS INC (US) 2005-10-05 CN claimed
CN-1675218-A Novel tricyclic spiropiperidines or spiropyrrolidines ASTRAZENECA AB (SE) 2005-09-28 CN claimed
CN-1509281-A Benzimidazol derivatives modulate che mokine receptors 2004-06-30 CN claimed
CN-1468233-A Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same ɪά��ʵ���� 2004-01-14 CN claimed
WO-2003053941-A2 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO claimed
EP-1189891-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-03-27 EP claimed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 WO claimed
CN-1236358-A Substituted N-[(aminoiminomethyl or aminomethyl) phenyl] propyl amides RHONE POULENC RORER PHARMA (US) 1999-11-24 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282810-A1 Chemical Synthesis Method and Application of V. Cholerae Serotype O100 O-Antigen Oligosaccharides DDOST, OGA, DAD1 HDAC1 1136/4885HDAC7 478/4885HDAC8 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.